<DOC>
	<DOCNO>NCT00268632</DOCNO>
	<brief_summary>The primary objective study assess impact physician 's reinforcement use bone marker data subject 's compliance ( least 50 % drug take ) persistence treatment one year postmenopausal osteoporotic woman .</brief_summary>
	<brief_title>IMPACT Study ( Improving Measurements Persistence `` ACtonel '' Treatment )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<criteria>Ambulatory woman , Caucasian , Oriental Multiracial previously diagnose osteoporosis . Females black descent US african american exclude low incidence postmenopausal osteoporosis use oral parenteral glucocorticoid ( &gt; = 5 mg prednisone equivalent per day ) within 3 month start study drug one month within six month prior study entry . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>